The Centre for Oncology and Immunology (COI), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), successfully hosted its 1st Flagship Symposium on July 11, 2024, titled “From Bench to Bedside to Business: Immuno-Oncology Translational Research, Clinical Trials, and Commercialization”.
This event brought together leading experts, researchers, and industry professionals from around the world, and featured a series of stimulating presentations and panel discussions that offered valuable insights into the translation of scientific research into clinical applications and commercial opportunities. Esteemed speakers included Dr Bradly Wouters and Dr Keith Stewart from UHN, who shared their expertise on conducting clinical and translational research at Princess Margaret Cancer Centre, as well as their insights into the commercialization process. In addition, Dr Jing Yang from Peking University presented his cutting-edge neuroimmuno-oncology research and Dr Christine Chio from Columbia University discussed her work on organoid models in pancreatic cancer. Many of COI’s researchers, including our co-director Prof. Tak Mak, also spoke or served as panellists, contributing to the rich exchange of knowledge and ideas.
A highlight of the symposium was the poster sessions, where young scientists from COI and UHN showcased their innovative research. The poster presentations covered a wide range of topics, reflecting the diverse and cutting-edge research being conducted. These sessions provided a platform for emerging researchers to present their work, receive feedback, and engage in meaningful discussions with fellow peers, senior scientists and industry leaders.
The symposium attracted over 300 attendees, including scientists, clinicians, and industry leaders from pharmaceutical and biotech companies, who had the opportunity to network and explore potential collaborations. This event highlighted COI's commitment to advancing the field of immuno-oncology and translating research into tangible benefits for patients. During the symposium, Prof Naoto Hirano emphasized the broader implications of COI’s research by stating, "Drug discovery goes beyond pure science; it must directly impact patient care. Achieving societal impact by developing a drug that truly helps patients is just as crucial as attaining scientific excellence." His words underscore COI’s goals and the symposium's theme of bridging the gap between research, clinical practice, and commercial development.
COI extends its heartfelt gratitude to all speakers, sponsors, and participants for their invaluable contributions to the symposium's success. We look forward to continuing our mission of promoting cutting-edge research and fostering a culture of innovation in oncology and immunology. Stay updated on COI’s latest news and research breakthroughs by following us on our social media platforms and visiting our website. Together, we can make a difference in the lives of those affected by cancer.